血脂康治疗不稳定型心绞痛的疗效观察

Lipid-lowering efficacy and safety of xuezhikang in patients with early-period of unstable angina

目的探讨血脂康治疗不稳定型心绞痛(UA)患者的疗效与安全性及对近中期心血管事件的影响。方法共入选84例不稳定型心绞痛患者,随机分为血脂康组(43例)和辛伐他汀组(41例):①血脂康组:43例UA患者,其中男性31例,女性12例。平均62.5岁。②辛伐他汀组:41例UA患者,其中男性30例,女性11例,平均年龄62.2岁。分别于3、6、12个月时复查血脂,并对临床事件作随访登记,同时观察用药安全性。结果血脂康组与辛伐他汀组均能有效降低UA患者血清总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平,随访期间两组均能使心肌梗死发生率、再住院率及再次血管重建率明显降低。两组之间比较差异无统计学意义。结论血脂康能有效降低UA患者血清TC及LDL-C水平,预防心血管事件的发生。具有良好的安全性和耐受性。

Objective To investigate whether early intervention is safe and may benefit to unstable angina patients, who are at risk of major events. Methods A randomized, open - lable, parallel group trial was conducted. A total of 84 eligible patients with unstable angina were enrolled. They were randomized either to xuezhikan or simvastatin treatment （xuezhikan group, n = 43 and simvastatin group, n =41 ）. Lipid levels were determined immediately after admission and 3, 6 and 12 months later. During the following - up, all adverse events and cardiovascular events were recorded. There were no significant differences in side effects and abnormal laboratory references between two groups. Results Levels of LDL - C and TC reduced significantly in the beth of groups. There are similar rates of AMI, re - hospitalization, and revascularization in beth groups. Conclusion The results suggest that early intervention with the HMG - CoA reductase inhibitor to UA is feasible and safe.